Search - tctmd.com

Displaying 181 - 200 of 284

Sort: Relevancy | Date

News Conference News ESC 2017

Mortality After Acute MI Halved Over Two Decades in Switzerland, With Greatest Gains by Women

Michael O'Riordan

August 26, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Michael O'Riordan

May 30, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

L.A. McKeown

March 14, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Noncardiac Surgery Riskier After Incomplete vs Complete Revascularization, Observational Study Finds

Yael L. Maxwell

February 01, 2017

News Daily News

Even With Early Invasive Strategy in NSTE ACS, Women Face Poorer Outcomes Than Men

Caitlin E. Cox

January 24, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

HIV-Positive Patients Face Elevated Rate of Type 2 MI

Caitlin E. Cox

January 12, 2017

Advertisement

Mortality After Acute MI Halved Over Two Decades in Switzerland, With Greatest Gains by Women

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

One in Five Acute MI Patients Drop Statins Within 2 Years

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Noncardiac Surgery Riskier After Incomplete vs Complete Revascularization, Observational Study Finds

Even With Early Invasive Strategy in NSTE ACS, Women Face Poorer Outcomes Than Men

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

HIV-Positive Patients Face Elevated Rate of Type 2 MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content